Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660553 | 1.00 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL28036934 | 0.86 | SIGMAR1 (0.60) | SIGMAR1 | |
| SCHEMBL20758864 | 0.86 | CXCR1 (0.46) | — | |
| SCHEMBL28036978 | 0.84 | GPR119 (0.53) | SIGMAR1 | |
| SCHEMBL28037412 | 0.84 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL9111641 | 0.83 | PARP15 (0.49) | — | |
| SCHEMBL20758197 | 0.83 | CHRNB2 (0.56) | SIGMAR1 | |
| SCHEMBL23634067 | 0.82 | F10 (0.41) | SIGMAR1 | |
| SCHEMBL31132814 | 0.81 | PARP10 (0.51) | — | |
| SCHEMBL28067029 | 0.79 | PARP10 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013743-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| CN-114502536-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2021030623-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2019035008-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-02-21 | — | — | WO | disclosed |
| CN-105153119-A | Pyridylpyrimidyl amine compounds or pyridylpyridyl amine compounds and application thereof | GUANGZHOU KEQIN NEW MEDICINE DESIGN CO LTD | 2015-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | SIGMAR1 4260/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | SIGMAR1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.